Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
239.56
-5.95 (-2.42%)
At close: Sep 18, 2026, 4:00 PM EDT
239.60
+0.04 (0.02%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Alnylam Pharmaceuticals Market Cap
Alnylam Pharmaceuticals has a market cap or net worth of $32.06 billion as of September 18, 2026. Its market cap has decreased by -45.86% in one year.
Market Cap
32.06B
Enterprise Value
31.73B
1-Year Change
-45.86%
Ranking
Category
Stock Price
$239.56
ChartMarket Cap Chart
Since June 1, 2004, Alnylam Pharmaceuticals's market cap has increased from $135.00M to $32.06B, an increase of 23,644.68%. That is a compound annual growth rate of 27.78%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 32.06B | -38.98% |
| Dec 31, 2025 | 52.54B | 73.09% |
| Dec 31, 2024 | 30.35B | 26.35% |
| Dec 29, 2023 | 24.02B | -17.84% |
| Dec 30, 2022 | 29.24B | 44.16% |
| Dec 31, 2021 | 20.28B | 34.32% |
| Dec 31, 2020 | 15.10B | 17.60% |
| Dec 31, 2019 | 12.84B | 74.32% |
| Dec 31, 2018 | 7.37B | -37.48% |
| Dec 29, 2017 | 11.78B | 266.69% |
| Dec 30, 2016 | 3.21B | -59.72% |
| Dec 31, 2015 | 7.98B | 6.90% |
| Dec 31, 2014 | 7.46B | 82.96% |
| Dec 31, 2013 | 4.08B | 326.36% |
| Dec 31, 2012 | 956.60M | 174.73% |
| Dec 30, 2011 | 348.20M | -16.32% |
| Dec 31, 2010 | 416.10M | -43.53% |
| Dec 31, 2009 | 736.80M | -28.05% |
| Dec 31, 2008 | 1.02B | -13.48% |
| Dec 31, 2007 | 1.18B | 71.64% |
| Dec 29, 2006 | 689.60M | 94.42% |
| Dec 30, 2005 | 354.70M | 136.47% |
| Dec 31, 2004 | 150.00M | 11.11% |
| Jun 1, 2004 | 135.00M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Moderna | 62.71B |
| argenx SE | 61.24B |
| Revolution Medicines | 42.56B |
| BeOne Medicines AG | 40.12B |
| Royalty Pharma | 33.79B |
| Roivant Sciences | 28.69B |
| Insmed | 27.04B |
| Incyte | 25.60B |